CFDE Data Portal | Search FSIP2-AS2

	Label	Description
	FSIP2-AS2 Gene (Entity type)	ENSG00000231646 - FSIP2 antisense RNA 2
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE209582 fluorouracil 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205674 TEPP-46 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE164529 tamoxifen 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

FSIP2-AS2

ENSG00000231646 - FSIP2 antisense RNA 2

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up

A Gene Set from LINCS

GSE176008 pyridoxine 4 v 3 human dn

A Gene Set from LINCS

GSE239844 crizotinib 7 v 2 human dn

A Gene Set from LINCS

GSE209582 fluorouracil 1 v 3 human up

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 2 v 5 human up

A Gene Set from LINCS

GSE205674 TEPP-46 0 v 1 human dn

A Gene Set from LINCS

GSE164529 tamoxifen 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.